靶向短肽介导的肿瘤抑素活性T3片段对骨肉瘤的疗效分析

Analysis of Curative Effect of Tumstatin Active T3 Fragment of Target Short Peptide Mediated on Osteosarcoma

目的分析研究靶向短肽介导的肿瘤抑素活性T3片段治疗骨肉瘤的临床治疗效果,为临床实践和相关理论的探讨提供±据。方法将肿瘤抑素活性T3片使用人工的方式合成,并且加上靶向短肽。分为体外研究和体内研究两种方式。体内试验选取40只小白鼠,针对它们制备骨肉瘤的相关模型,然后将骨肉瘤较大的小白鼠和骨肉瘤较小的小白鼠全部排除在实验之外,剩下的小白鼠分组进行实验。分为四组,每组小白鼠四只。使用化疗药物、T3肽、磷酸盐液以及靶向-T3肽分别进行治疗。治疗一段时间后,称量肿瘤的重量,并且对肿瘤组织免疫染色、对小白鼠肺部相关组织进行染色,从而对靶向-T3肽对骨肉瘤的抑制作用进行分析。体外实验包括细胞迁移抑制实验,这样的实验方法为了检测靶向-T3肽对人体静脉血管中的内皮细胞的抑制情况。结果体内实验组中,靶向-T3肽肿瘤的平均重量为(1.009±0.198)g,抑制肿瘤的概率为45.96%。 T3肽肿瘤的平均重量为(1.507±0.324)g,抑制肿瘤的概率为27.89%。肿瘤重量方面,各组具有统计学差异(<0.05)。化疗药物以及磷酸盐液检查分析发现,靶向-T3肽抑制肿瘤的成效要优于T3肽。体外实验组,T3肽和靶向-T3肽对人体静脉血管中的内皮细胞均有抑制作用。结论靶向短肽介导的肿瘤抑素活性T3片段在骨肉瘤临床治疗中疗效显著,临床具有广泛应用价值。

Objective Clinical analysis of curative effect of tumstatin active T3 fragment ofosteosarcoma therapy targeting peptide mediated,thus to provide a basis forclinical practice and related theory.Methods The tumstatin active T3 using synthetic artificial way,plus target short peptide.For in vitro and in vivo in two ways.In vivo test to select 40 mice,according to the related model preparationof osteosarcoma,and then the rat osteosarcoma larger mice andosteosarcoma smaller eliminated in experiment,mice were grouped the remaining experiments.Divided into four groups,each group of four mice were.The use of chemotherapy drugs,T3 peptide,phosphate buffer and-T3 targeting peptide were treatment.After a period of treatment,tumor weightweighing,and dyeing,on tumor immune of mice lung tissue were stained,andanalysis of-T3 targeting peptide inhibition on osteosarcoma were.In vitro experiments including cell migration inhibition,inhibition of these methods in order to detect the target-T3 peptide on human vascular endothelial cells in.Results In the experimental group,the average weight of-T3 tumor targetingpeptide was(1.009±0.198)g,the probability of tumor suppression was 45.96%.The average weight of T3 peptide tumor was(1.507±0.324)g,the probability of tumor suppression was 27.89%.The tumor weight of each group,with statistical dif erence(<0.05).Chemotherapy drugs and phosphate fluid examination analysis,targeting-T3 peptide tumor inhibition ef ect was bet er than that of T3 peptide.In vitro experimental group,T3 peptide and targeting of-T3 peptide on human vascular endothelial cells showed the inhibition in the.Conclusion Tumstatin active T3 fragment of target short peptide mediated remarkable curative effect in the clinical treatment of osteosarcoma,clinical has the widespread application value.